2.48

0.40% -0.01

After Hours: 2.52 0.04 +1.61%

Moleculin Biotech Inc (MBRX)

Overview News Price History Financials Discussions Forecast Stock Split

Moleculin Biotech Inc stock is traded at $2.48, with a volume of 53,649. It is down -0.40% in the last 24 hours and up +6.90% over the past month. Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Previous Close:

$2.49

Open:

$2.49

24h Volume:

53,649

Relative Volume:

0.35

Market Cap:

$13.23M

Revenue:

Net Income/Loss:

$-23.92M

P/E Ratio:

-0.0985

EPS:

-25.1834

Net Cash Flow:

$-22.74M

1W Performance:

-1.20%

1M Performance:

+6.90%

6M Performance:

-78.27%

1Y Performance:

-90.27%

1-Day Range:

$2.48

$2.55

1-Week Range:

$2.425

$2.5938

52-Week Range:

$1.79

$28.61

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name

Moleculin Biotech Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

713-300-5160

Address

5300 MEMORIAL DRIVE, HOUSTON, TX

Employee

Twitter

@moleculinbio

Next Earnings Date

2026-05-12

Latest SEC Filings

MBRX's Discussions on Twitter

Compare MBRX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MBRX Moleculin Biotech Inc	2.48	13.29M	0	-23.92M	-22.74M	-25.18
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-09-25	Resumed	H.C. Wainwright	Buy
Feb-12-25	Downgrade	Maxim Group	Buy → Hold
Jul-18-22	Resumed	Oppenheimer	Outperform

Moleculin Biotech Inc Stock (MBRX) Latest News

May 04, 2026

MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill

May 04, 2026

May 02, 2026

Why did MBRX stock climb 14% today? - MSN

May 02, 2026

Apr 27, 2026

MBRX Forecast, Price Target & Analyst Ratings | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill

Apr 27, 2026

Apr 25, 2026

Moleculin Biotech files to sell 6.37M shares of common stock for holders - MSN

Apr 25, 2026

Apr 23, 2026

Moleculin Biotech Announces Annamycin Significantly Extends Survival in Preclinical Pancreatic Cancer Models at AACR 2026 - Minichart

Apr 23, 2026

Moleculin Highlights Promising Preclinical Data for L-ANN - TipRanks

Apr 23, 2026

Moleculin Biotech, Inc. Reports Promising Preclinical Results for Annamycin in Pancreatic Cancer Treatment - Quiver Quantitative

Apr 23, 2026

[8-K] Moleculin Biotech, Inc. Reports Material Event - Stock Titan

Apr 23, 2026

In pancreatic cancer models, Moleculin drug stretched survival to 29 days - Stock Titan

Apr 23, 2026

Apr 21, 2026

Moleculin Biotech, Inc. Announces Poster Presentation at ASCO 2026 Highlighting Cardiac Safety of Annamycin - Quiver Quantitative

Apr 21, 2026

Cancer drug heart-safety data earns Moleculin an ASCO poster slot - Stock Titan

Apr 21, 2026

Moleculin Biotech stock (US60855L2034): Is its oncology pipeline strong enough to drive investor ret - AD HOC NEWS

Apr 21, 2026

Apr 20, 2026

Moleculin Biotech stock (US60855L2034): Is its cancer drug pipeline strong enough to drive investor - AD HOC NEWS

Apr 20, 2026

Apr 17, 2026